PMID- 36908199
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230317
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 29
DP  - 2023 Jan-Dec
TI  - Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit 
      Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin.
PG  - 10760296231163251
LID - 10.1177/10760296231163251 [doi]
LID - 10760296231163251
AB  - Introduction: Bovine and ovine mucosa represent alternate anticoagulants to 
      porcine mucosa for production of unfractionated heparin (UFH). Standardized 
      heparins from various sources can be blended and potency adjusted, blended 
      heparins exhibit comparable effects as single-sourced porcine UFH. This study 
      evaluated the pharmacologic profile of blended heparin and compared their 
      activities to that of single sourced porcine, ovine, and bovine heparins. 
      Methods: The anticoagulant effects of gravimetric and potency-adjusted heparins 
      were evaluated with aPTT, TT, anti-Xa, anti-IIa, ACT, and TGA studies. Protamine 
      sulfate studies were used for neutralization potential of each of the individual 
      heparins. Results: The potency-adjusted heparins demonstrated comparable aPTT, 
      TT, anti-Xa, anti-IIa, and ACT values at all concentrations (U/mL). However, in 
      gravimetric studies, bovine heparin consistently showed lower values with the 
      exception of thrombin generation inhibition studies. The protamine sulfate 
      neutralization studies demonstrated complete neutralization at all concentrations 
      for the potency-adjusted heparins. However, at gravimetric concentrations, minor 
      differences were noted in the neutralization profile in each of these heparins. 
      Conclusion: These studies support the hypothesis that blended heparin from 
      bovine, ovine, and porcine tissue, when standardized in unit-equivalent 
      proportions, exhibits a comparable anticoagulant profile to the single species 
      derived heparins.
FAU - Olson, Guy
AU  - Olson G
AUID- ORCID: 0000-0003-3454-2273
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Jeske, Walter
AU  - Jeske W
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Iqbal, Omer
AU  - Iqbal O
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Krupa, Emily
AU  - Krupa E
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Farooqui, Amber
AU  - Farooqui A
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Siddiqui, Fakiha
AU  - Siddiqui F
AUID- ORCID: 0000-0002-2219-7049
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
AD  - Program in Health Sciences, 16728UCAM - Universidad Catolica San Antonio de 
      Murcia, Murcia, Spain.
FAU - Hoppensteadt, Debra
AU  - Hoppensteadt D
AUID- ORCID: 0000-0001-9342-4213
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Kouta, Ahmed
AU  - Kouta A
AUID- ORCID: 0000-0001-7579-9572
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
FAU - Fareed, Jawed
AU  - Fareed J
AUID- ORCID: 0000-0003-3465-2499
AD  - Cardiovascular Research Institute, Section of Hemostasis and Thrombosis, 
      25815Loyola University Medical Center, Maywood, IL, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 9005-49-6 (Heparin)
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Protamines)
RN  - 0 (Biological Products)
SB  - IM
MH  - Animals
MH  - Sheep
MH  - Cattle
MH  - Swine
MH  - *Heparin/pharmacology
MH  - Anticoagulants/pharmacology
MH  - Heparin, Low-Molecular-Weight/pharmacology
MH  - Protamines
MH  - *Biological Products
PMC - PMC10014986
OTO - NOTNLM
OT  - USP reference heparin
OT  - anticoagulant assays
OT  - blended heparins
OT  - gravimetric
OT  - heparin
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/03/14 06:00
MHDA- 2023/03/15 06:00
PMCR- 2023/03/12
CRDT- 2023/03/13 02:33
PHST- 2023/03/13 02:33 [entrez]
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/03/12 00:00 [pmc-release]
AID - 10.1177_10760296231163251 [pii]
AID - 10.1177/10760296231163251 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231163251. doi: 
      10.1177/10760296231163251.